Developments and Recent Trends in Cell and Gene Therapies for Cancer
- 1st Edition - March 1, 2027
- Latest edition
- Editors: Ranjita Shegokar, Yashwant Pathak
- Language: English
Developments and Recent Trends in Cell and Gene Therapies for Cancer is a comprehensive and strategic reference that explores the scientific foundations, clinical applic… Read more
Description
Description
Key features
Key features
- Focuses on a single FDA-approved therapy, offering a consistent and detailed format that includes development history, mechanism of action, clinical indications, and outcomes—making it easy for readers to find targeted, actionable insights
- Bridges foundational science with commercialization pathways, regulatory considerations, and translational challenges—ideal for both researchers and biotech professionals
- Ensures authoritative content and diverse perspectives, enhancing its value as a reference for oncology, drug development, and policy-making
Readership
Readership
Table of contents
Table of contents
2. ADSTILADRIN (nadofaragene firadenovec-vcng)
3. ALLOCORD (HPC, Cord Blood)
4. AMTAGVI (lifileucel)
5. AUCATZYL (obecabtagene autoleucel)
6. BEQVEZ (fidanacogene elaparvovec-dzkt)
7. BREYANZI (lisocabtagene maraleucel)
8. CARVYKTI (ciltacabtagene autoleucel)
9. CASGEVY (exagamglogene autotemcel [exa-cel])
10. CLEVECORD (HPC Cord Blood)
11. DUCORD (HPC Cord Blood)
12. ELEVIDYS (delandistrogene moxeparvovec-rokl)
13. ENCELTO (revakinagene taroretcel-lwey)
14. GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen)
15. HEMACORD (HPC, Cord Blood)
16. HEMGENIX (etranacogene dezaparvovec-drlb)
17. HPC, Cord Blood – Clinimmune Labs
18. HPC, Cord Blood – MD Anderson Cord Blood Bank
19. HPC, Cord Blood – LifeSouth
20. HPC, Cord Blood – Bloodworks
21. IMLYGIC (talimogene laherparepvec)
22. KEBILIDI (eladocagene exuparvovec-tneq)
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 1, 2027
- Language: English
About the editors
About the editors
RS
Ranjita Shegokar
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)
YP